Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nutraquest bankruptcy

This article was originally published in The Tan Sheet

Executive Summary

Manasquan, N.J.-based firm, formerly known as Cytodyne Technologies, estimates its debt at between $50 mil. and $100 mil. and assets at $10 mil. to $50 mil. in Oct. 16 Chapter 11 filing. Filing puts federal and state lawsuits related to Cytodyne's ephedra-containing and ephedra-free Xenadrine products, including a hold on wrongful death suit filed by widow of Orioles pitcher Steve Bechler (1"The Tan Sheet" July 21, 2003, p. 3). Cytodyne President Robert Chinery formed Nutraquest in June when Cytodyne licensed rights to all its products to Xenadrine manufacturer Phoenix Labs (2"The Tan Sheet" June 23, 2003, p. 13)...
Advertisement

Related Content

Xenadrine Safety Misrepresentations Alleged In Bechler Suit v. Cytodyne
Xenadrine Safety Misrepresentations Alleged In Bechler Suit v. Cytodyne
Cytodyne Products’ Distribution And Sales Rights Licensed To Phoenix Labs

Topics

Advertisement
UsernamePublicRestriction

Register

PS096096

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel